If you have been reading about Research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-21. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
== Physiological distribution == Lipases are involved in diverse biological processes which range from routine metabolism of dietary triglycerides to cell signaling and inflammation. Thus, some lipase activities are confined to specific compartments within cells while others work in extracellular spaces.
=== Uniforms === Battledress - Used until the 1960s Boots, General Service Khaki drill Denison smock - Used in airborne units until the 1970s 1950 Pattern Jungle Green Dress Boots, Tropical Jungle 1960 Pattern Combat Dress - Produced in olive green and then in Disruptive Pattern Material. Boots, Directly Moulded Sole 1968 Pattern No. 8 Combat Dress - Produced in Disruptive Pattern Material. Smock Parachutist DPM Lightweight Trousers - Produced in olive green No. 9 Tropical Dress 1984 Pattern Combat Dress Boots, Combat, High
=== Legal status === As of 2011, dezocine is not used in the United States or Canada. It is not commercially available in either of these countries, nor is it offered as a prescribed analgesic for postoperative care. In China however, it is commonly used after surgery.
Sources: en.wikipedia.org
By some estimates, this might account for most of the internal radiation damage, as the recoil nucleus is part of an atom that is much larger than an alpha particle, and causes a very dense trail of ionization; the atom is typically a heavy metal, which preferentially collect on the chromosomes. In some studies, this has resulted in an RBE approaching 1,000 instead of the value used in governmental regulations. The largest natural contributor to public radiation dose is radon, a naturally occurring, radioactive gas found in soil and rock. If the gas is inhaled, some of the radon particles may attach to the inner lining of the lung. These particles continue to decay, emitting alpha particles, which can damage cells in the lung tissue. The death of Marie Curie at age 66 from aplastic anemia was probably caused by prolonged exposure to high doses of ionizing radiation, but it is not clear if this was due to alpha radiation or X-rays. Curie worked extensively with radium, which decays into radon, along with other radioactive materials that emit beta and gamma rays. However, Curie also worked with unshielded X-ray tubes during World War I, and analysis of her skeleton during a reburial showed a relatively low level of radioisotope burden. The Russian defector Alexander Litvinenko's 2006 murder by radiation poisoning is thought to have been carried out with polonium-210, an alpha emitter.
== Qualifying == Teams that were not members of either the Premier League or English Football League competed in the qualifying rounds to secure one of 32 available places in the first round. On 6 August 2022, in an extra preliminary round match against Fleet Town, Newport (IOW) teenager Finn Smith became the youngest ever FA Cup goalscorer, a day after his 16th birthday. The fourth and final qualifying round was played on the weekend beginning 15 October. The winners from the fourth qualifying round were Oldham Athletic, AFC Fylde, King's Lynn Town, York City, South Shields, Curzon Ashton, Wrexham, Solihull Moors, Gateshead, Chesterfield, Alvechurch, Buxton, Coalville Town, FC Halifax Town, Torquay United, Maidenhead United, Hereford, Taunton Town, Eastleigh, Woking, Dagenham & Redbridge, Ebbsfleet United, Chippenham Town, Weymouth, Oxford City, Bracknell Town, Needham Market, Chelmsford City, Boreham Wood, Merthyr Town, Farnborough and Barnet. Needham Market was the only club in this season's tournament appearing in the competition proper for the first time, although reconstituted sides Merthyr Town and Farnborough were featuring at this stage for the first time in their own right following the liquidation of Merthyr Tydfil FC (in 2010) and Farnborough Town (in 2007). Of the others, Weymouth had last appeared in the first round in 2007-08, Coalville Town had last done so in 2004–05, Bracknell Town had last done so in 2000-01 and Alvechurch had last done so in 1973-74.
== External links == Adrenochrome Commentary at erowid.org Adrenochrome deposits resulting from the use of epinephrine-containing eye drops used to treat glaucoma from the Iowa Eye Atlas (searched for diagnosis = adrenochrome) QAnon's Adrenochrome Quackery, Joe Schwarcz, 10 Feb 2022, Office for Science and Society, McGill University
Here, the resulting dimer has a stoichiometry different from the initial pair of monomers. Disaccharides need not be composed of the same monosaccharides to be considered dimers. An example is sucrose, a dimer of fructose and glucose, which follows the same reaction equation as presented above. Amino acids can also form dimers, which are called dipeptides. An example is glycylglycine, consisting of two glycine molecules joined by a peptide bond. Other examples include aspartame and carnosine.
Sources: en.wikipedia.org
Because higher fungal classification has changed substantially over time, some fungaria have shifted from detailed taxonomic hierarchies to alphabetical arrangement within broader groups, using collection databases to manage retrieval more efficiently. Even detailed digital catalogues and specimen images do not eliminate the need for preserved material, because internal, microscopic, chemical, and genetic characters may still require direct examination, and new analytical methods can reveal characters that were not anticipated when a specimen was first catalogued.
== Career == In the 1990s, Laukien was a lecturer in NMR and mass spectrometry at the University of Bremen, Germany, and a part-time professor at the Institute of Mass Spectrometry of the University of Amsterdam, Netherlands. He has previously served on the Dean's Advisory Committee of the School of Science of MIT, and on the Board of the Analytical, Life Science & Diagnostics Association (ALDA), including one year as chairman. In 2017, he has been elected a senator of acatech, the German natural science and engineering academy. Laukien owns 24% of Bruker. As of October 2020, Forbes estimated his net worth at US$1.5 billion.
== Clinical significance == LPS exposure induces LBP production. LBP is synthesized by the liver, adipose tissue, and intestinal cells. Dietary glucose and saturated fats acutely increase plasma LBP. The proinflammatory activity of plasma LPS is increased by LBP, which is higher in obesity. Plasma LBP is used as a better biomarker of plasma LPS than LPS itself due to the short half-life of LPS.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.